Komentář ke studii "Ponatinib u pacientů s CML - konsenzus léčby a management pacientů podle evropského panelu expertů"
| Title in English | Commentary on the study "Ponatinib in CML patients - Consensus treatment and patient management according to the European panel of experts" |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical (without peer review) |
| MU Faculty or unit | |
| Citation | |
| Description | Currently, five tyrosine kinase inhibitors (TKIs) are approved for the treatment of chronic myeloid leukemia (CML) in the European Union. Three are designated for line 1 (imatinib, nilotinib and dasatinib) and two for resistance or intolerance (bosutinib and ponatinib). Their indication criteria partially overlap. In particular, consideration of specific factors such as CML phase, mutation status or treatment lines is the key to choosing the right TKI. However, other factors such as other patient's disease, drug interactions, or TKI safety profile are involved in decision-making. Ponatinib has already shown its efficacy in the treatment of refractory CML, but its use may be accompanied by an increased risk of cardiovascular (CV) events. Experts from all over Europe have discussed their clinical experience in the treatment of CML patients through online debates and repeated face-to-face meetings in the framework of the European Expert Panel. Scenarios have been described in which CML patients may be suitable candidates for treatment with ponatinib. The current consensus on the care of CML patients that emerged from these discussions is presented here, including representative cases from clinical practice (case studies). |